Condition: Advanced Solid Tumor · Sponsor: University Hospital, Basel, Switzerland
The main objective of this study is to test if adding the mistletoe extract Iscador® Qu to regular cancer treatment with immune checkpoint inhibitors affects: * The immune system's ability to fight cancer * Safety of the treatment * How well the treatment performs against cancer * How the patient feels during treatment Researchers will compare patients treated with immune checkpoint inhibitors plus Iscador® Qu with patients treated with imune checkpoint inhibitors only.
This description comes directly from the study's public registry record.
Mascha Binder, Prof. Dr. · +41 61 265 50 75 · mascha.binder@unibas.ch
Benjamin Kasenda, PD Dr. Dr. · +41 61 265 50 75 · Benjamin.Kasenda@usb.ch
Always discuss trial participation with your own doctor first.
| Kantosspital Baden AG | Baden, Switzerland | Recruiting |
| Universitätsspital Basel | Basel, Switzerland | Recruiting |
| Kantonsspital Baselland | Liestal, Switzerland | Recruiting |
| Tumor- und Brustzentrum Ostschweiz | Sankt Gallen, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06408688